# Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

> **NCT02406183** · PHASE1 · COMPLETED · sponsor: **Radiotherapie** · enrollment: 13 (actual)

## Conditions studied

- Melanoma
- Effects of Immunotherapy
- Adverse Effect of Radiation Therapy

## Interventions

- **RADIATION:** Stereotactic body radiotherapy (SBRT)
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02406183
- **Lead sponsor:** Radiotherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406183, "Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02406183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*